Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents’ patients
| Fatma SE Ebeid, MD | |
| +201095569596 | |
| [email protected] |
2 Years - 18 Years
Phase 4
Interventional
All
Drug
Other
Children and adolescents diagnosed with sickle cell disease by haemoglobin electrophoresis and had at least two pain crises (no upper limit) documented during the previous year; a pain crisis is defined as pain leading to treatment with a parenteral administered narcotic or ketolac in an emergency department (ED) (or outpatient treatment centre) or during hospitalization.
Patients receiving hydroxyurea at a fixed dose for at least 3 months before screening.
Patients with sickle cell trait and other hemoglobinopathy.
–